Humacyte Q2 net loss widens on inventory, production costs

Humacyte

12/08/2026 12:11

Overview
U.S. bioengineered tissue maker's Q2 net loss widened, missing analyst expectations
Q2 product revenue for Symvess rose to $0.4 mln from $0.1 mln a year earlier
Company plans sBLA filing for dialysis access after breakthrough Phase 3 results for ATEV

Outlook
Humacyte plans to file sBLA for ATEV dialysis access with FDA in H2 2026
Company expects to start Phase 2a CTEV CABG study in Q3 2026
Humacyte reports strengthening Symvess adoption and utilization in influential hospitals in H2 2026

Result Drivers
COMMERCIAL STRATEGY SHIFT - Co said Q2 Symvess sales growth was driven by rebuilding its commercial team, refining pricing incentives, and targeting hospital adoption, per Chief Commercial Officer Jim Mercadante
INVENTORY AND PRODUCTION COSTS - Q2 cost of goods sold rose due to a $0.7 mln inventory reserve and overhead from unused production capacity
REDUCED R&D SPENDING - Q2 research and development expenses fell due to fewer non-commercial manufacturing runs and lower clinical trial costs

Company press release: ID:nGNX4C0GDk

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
Miss
$36.80 mln
$22.79 mln (5 Analysts)
Q2 Operating Income
Miss
-$27 mln
-$22.07 mln (5 Analysts)
Q2 Loss Per Basic Share
 
$0.16
 
Q2 Operating Expenses
 
$27.40 mln
 

Reuters Recommended Reads
Aug 10 - Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Aug 11 - Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses
Aug 11 - Pliant Therapeutics Q2 net loss narrows on operating expenses decline, reduced headcount

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)